#pharma

7개의 글

July 20, 2026

Jeil Pharmaceutical (271980) Stock Outlook 2026: A Low-Margin Drug-Distribution Cash Cow With a P-CAB Option Attached

Jeil Pharmaceutical group (Jeil Pharma Holdings, KRX: 271980) 2026 stock analysis: a low-margin base of distributing multinational in-licensed drugs, layered with a re-rating option from subsidiary Onconic Therapeutics' P-CAB reflux drug zastaprazan (Jaqbo) — domestic launch plus a China out-licensing royalty. Bull case, competition versus K-CAB and Fexuclue, holding-company structure, and what global investors should watch.

Jeil Pharmaceutical Jeil Pharma Holdings 271980

July 14, 2026

INSM (Insmed) Stock Outlook 2026: Inside a Catalyst-Driven Rare-Disease Biotech

INSM (Insmed) stock outlook for 2026. A qualitative deep dive into the Arikayce revenue base for NTM lung disease, the brensocatib bronchiectasis catalyst, the TPIP pulmonary hypertension pipeline, and the commercialization-transition and cash-burn risks that define this late-stage biotech.

INSM Insmed rare disease

July 13, 2026

VTRS (Viatris) Stock Outlook 2026: The Dividend and Deleveraging Case for a Generics Giant

Viatris (VTRS) 2026 stock outlook. A qualitative deep dive into the Pfizer Upjohn-Mylan merger, the debt paydown and dividend story, brand-revenue decline offset by complex generics and biosimilars, EpiPen's fading pricing power, and the key risks.

VTRS Viatris generic drugs

June 30, 2026

Chong Kun Dang (185750) Stock Outlook 2026: Incremental-Drug Cash Cow Meets a Novel Pipeline Re-Rating

A qualitative 2026 outlook on Chong Kun Dang (KRX: 185750), the Korean pharma whose K-CAB-led incremental drugs fund a diversifying novel-drug pipeline. We unpack the cash-cow base, licensing-out and royalty optionality, operating margins and R&D, drug-price pressure, peer positioning, and what global investors should monitor each quarter.

Chong Kun Dang 185750 Korea Stocks

June 24, 2026

HK inno.N (195940) Stock Outlook 2026: A Homegrown P-CAB Blockbuster and Single-Product Risk

HK inno.N (KRX 195940) 2026 stock outlook. A qualitative deep dive into K-CAB (tegoprazan), Korea's homegrown P-CAB reflux drug and its competitive moat, the global licensing-out model, US clinical ambitions, the Condition hangover brand and IV-fluid base business, plus single-product dependence and drug-pricing risk for international investors.

HK inno.N 195940 K-CAB

June 23, 2026

Yuhan Corporation Stock Outlook 2026: A Value Pharma Re-Rated by a J&J Oncology Royalty

Yuhan Corporation (KRX: 000100) 2026 stock analysis: a stable base of prescription, OTC, consumer-health and API businesses meets a transformational catalyst — lazertinib (Lazcluze/Leclaza), out-licensed to Johnson & Johnson, generating milestone and royalty income in EGFR lung cancer. Bull case, single-asset risk, governance, and what global investors should watch.

Yuhan 000100 Korea Stocks